“Exploiting mitochondrial and oxidative vulnerabilities with a synthetic analog of pancratistatin in combination with piperlongumine for cancer therapy”
Researchers from the University of Windsor recently identified several highly active analogues of the natural compound Pancratistatin (PST) that selectively induce apoptosis in cancer cells. By disrupting mitochondrial function, they cause the dissipation of mitochondrial membrane potential and decrease oxygen consumption.1
In a new study, the researchers now demonstrate how combined treatment of cells with PST analogues and Piperlongumine, a compound known to induce the accumulation of ROS, can significantly increase the apoptosis-inducing activity of the PST-analogues selectively in cancer cells. This combined targeting of mitochondrial and oxidative stress vulnerabilities promises to be an effective strategy for cancer therapy and will potentially decrease the severity of the adverse side-effects of current chemotherapeutics.
In both studies, the MitoXpress® Xtra Oxygen Consumption Assay was used as a key tool to identify and validate the mode of action of the PST analogues. Luxcel Biosciences is thrilled our versatile assays were able to contribute to the ongoing fight against cancer.
Read the Full Article:
Ma, D., Gilbert, T., Pignanelli, C., Tarade, D., Noel, M., Mansour, F., Gupta, M., Ma, S., Ropat, J., Curran, C., Vshyvenko, S., Hudlicky, T. and Pandey, S. (2017). Exploiting mitochondrial and oxidative vulnerabilities with a synthetic analog of pancratistatin in combination with piperlongumine for cancer therapy. The FASEB Journal, p.fj.201700275R. http://www.fasebj.org/content/early/2017/09/14/fj.201700275R
1 Ma, D., Pignanelli, C., Tarade, D., Gilbert, T., Noel, M., Mansour, F., Adams, S., Dowhayko, A., Stokes, K., Vshyvenko, S., Hudlicky, T., McNulty, J. and Pandey, S. (2017) Cancer Cell Mitochondria Targeting by Pancratistain Analogs is Dependent on Functional Complex II and III. Scientific Reports 7:42957. https://www.nature.com/articles/srep42957